Issues & Trends

JEONJINBIO CO., LTD.: "Expanding Supply of New Home Care Products… Targeting the Global Market"

Shin Ha-yeon
2026-07-22 13:43:56
[Edaily Reporter Shin Ha-yeon ] JEONJINBIO CO., LTD.(110020)announced on the 22nd that it is expanding the supply of its new home care product line to target the global market.

The company recently finalized a deal to supply new home care products to a global distribution firm with annual revenue of 2 trillion won on a consolidated basis, both domestically and internationally. These products, which form a new home care line following the company’s existing flagship item—capsule detergent—are scheduled to be supplied to domestic and international distribution networks after passing quality verification by the global client.
A view of JEONJINBIO CO., LTD.’s headquarters. (Photo: JEONJINBIO CO., LTD.)

JEONJINBIO CO., LTD. plans to use this supply agreement as an opportunity to increase the proportion of overseas sales in its home care business and strengthen cooperation with global partners. The company intends to leverage its partners’ global distribution networks to increase market share while simultaneously pursuing revenue growth and improved profitability in this business segment.

JEONJINBIO CO., LTD. official stated, “Following our existing capsule detergents, our new home care products also meet the strict standards of our global partners, allowing us to expand our supply contracts,” adding, “Based on our sales network and technological capabilities, we will continuously increase overseas supply volumes to cultivate the home care business as a core growth engine.”

Economy

Corporation

IT·Science

Corporation

HYUNDAILIVART Wins the Director-General of the Korea Agency for Technology and Standards Award at the '2026 Good Design Awards'

HYUNDAILIVART, which is targeting the office furniture market, has received recognition for its designs developed to reduce physical strain even in environments with long working hours. The FITTER …
2026-10-27 09:46:11

IT·Science

DB Securities: “Aptabio Therapeutics Inc.’s APX115: Expectations for Technology Export Grow Following Clinical Results for Acute Kidney Injury”

DB Securities assessed that the prospects for a global technology export have increased for “Isuzinaxib” (APX115), a kidney disease treatment developed by Aptabio Therapeutics Inc.(293780), after it d…
2026-10-27 10:09:02